Thanks for having us Ehab Youssef James Rouse A touching experience combined later with the breathtaking views from Roche Tower 2. Why does this matter? It reveals the importance of: → Cutting ...

Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...

What are the available listings for 2 bedroom apartments for rent in The Gate Tower? On Bayut, the number of currently listed 2 bedroom rental apartments in The Gate Tower is 113. At what price ranges ...

Sahara Tower 2 is a six-building residential complex in Al Nahda, Sharjah. It is known as the Sahara Tower Complex. Tower 2 has 15 floors for apartments. There are 135 units in this building. There ...

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer and said it is analyzing the proposal before deciding on the next steps.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Paul Delaroche’s Execution of Lady Jane Grey is a mesmerizing piece that captures the essence and tragedy of one of England’s most ill-fated queens, who was beheaded at the Tower of London at just 17.

Find out what everyone is searching for this year, from a Kendra Scott necklace to a Cuisinart ice cream maker.

Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion. The Financial Times first revealed the ...

Developer Ryan Companies US Inc., in collaboration with architecture firm Gensler, finished construction on the high-rise Nov ...

Local roaster Tenfold Coffee Co. opened a European-inspired, all-day café Nov. 19 in Norton Rose Fulbright Tower, which opened last year and was previously known as 1550 on the Green. The new location ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...